These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23894481)

  • 1. Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases.
    Smits ML; van den Hoven AF; Rosenbaum CE; Zonnenberg BA; Lam MG; Nijsen JF; Koopman M; van den Bosch MA
    PLoS One; 2013; 8(7):e69448. PubMed ID: 23894481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
    Memon K; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Gates VL; Atassi B; Newman S; Omary RA; Benson AB; Salem R
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):887-94. PubMed ID: 22137020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kurilova I; Beets-Tan RGH; Ulaner GA; Boas FE; Petre EN; Yarmohammadi H; Ziv E; Deipolyi AR; Brody LA; Gonen M; Sofocleous CT
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1419-1427. PubMed ID: 29766239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
    Jia Z; Wang W
    Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioembolization with
    Braat AJAT; Ahmadzadehfar H; Kappadath SC; Stothers CL; Frilling A; Deroose CM; Flamen P; Brown DB; Sze DY; Mahvash A; Lam MGEH
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):246-253. PubMed ID: 31646375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
    Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
    Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
    Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
    Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
    Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
    BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
    Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
    J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach.
    Seidensticker R; Seidensticker M; Damm R; Mohnike K; Schütte K; Malfertheiner P; Van Buskirk M; Pech M; Amthauer H; Ricke J
    Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1109-18. PubMed ID: 22037709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
    Kim AY; Frantz S; Brower J; Akhter N
    J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer.
    Kennedy AS; Ball DS; Cohen SJ; Cohn M; Coldwell D; Drooz A; Ehrenwald E; Kanani S; Rose SC; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA;
    Clin Colorectal Cancer; 2016 Jun; 15(2):141-151.e6. PubMed ID: 26541321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
    Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
    J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.